Mucosis Signs Research and License Option Agreement with Crucell
Mucosis BV, a clinical-stage Dutch biotechnology company developing innovative mucosal vaccines, today announced that it…
Mucosis BV, a clinical-stage Dutch biotechnology company developing innovative mucosal vaccines, today announced that it…
Biotech companies ExpreS2ion Biotechnologies and Mucosis, along with University of Copenhagen today announced that they…
Mucosis B.V., the Dutch clinical-stage biotechnology company developing mucosal vaccines, today announced the appointmen…
Dutch vaccine development company Mucosis B.V. today announced Phase I clinical data providing proof-of-concept that Mim…
Dutch biotechnology company Mucosis B.V. today announced the publication in the peer-reviewed journal Vaccine of preclin…
Dutch biotechnology company Mucosis B.V. today announced that it has appointed professors Jiri Mestecky, M.D., Ph.D.; Wi…
Dutch biotechnology company Mucosis B.V. today announced the appointment of Thomas Johnston as Chief Business Officer. I…
Dutch biotechnology company Mucosis B.V. announced today that Dr. Barry Buckland was elected to its Supervisory Board. D…
Dutch biotechnology company Mucosis B.V. announced today that it has entered into a collaboration agreement with the glo…
Dutch biotechnology company Mucosis B.V. announced today that John Lambert was elected as member and chair of its Superv…